Analysts' Top 5 Price Targets of June 16, 2025
Reading Time: 3 minutes
Incyte [US45337C1027]: Stifel upgrades from Hold to Buy with a price target of $107 (53% upside potential) Incyte presented promising initial clinical data on INCA033989 at the EHA Congress 2025 in Milan – a novel first-in-class targeted monoclonal antibody aimed at mutated Calreticulin (mutCALR) in myeloproliferative neoplasms (MPN). The data show that INCA033989 led to a rapid and sustained normalization of platelet counts across all dosing levels examined. These initial clinical results underscore the potential of the antibody as a targeted...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
